<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37429671</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000923</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000923</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Cognitive dysfunction (CD) is detectable in approximately 40% of patients with SLE. Despite this high prevalence, there are no approved pharmacological treatment options for this detrimental condition. Preliminary murine studies show potential for targeting microglial activation as a treatment of SLE-CD, which may be ameliorated with centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use. The aim of this study is to determine if there is an association of cACEi/cARB use with cognitive function in a human SLE cohort.</AbstractText><AbstractText Label="METHODS">The American College of Rheumatology neuropsychological battery was administered to patients with consecutive SLE at a single academic health centre at baseline, 6 and 12 months. Scores were compared with sex-matched and age-matched control subjects. Clinical and demographic data were gathered at each visit. The primary outcome was CD defined as dysfunction in two or more cognitive domains. The primary predictor was a total cumulative dose of cACEi/cARB in milligrams per kilogram, recorded as an equivalent ramipril dose. Odds of CD with respect to cACEi/cARB use were determined through generalised linear mixed modelling.</AbstractText><AbstractText Label="RESULTS">A total of 300 patients, representing 676 visits, completed this study. One hundred sixteen (39%) met the criteria for CD. Fifty-three participants (18%) were treated with a cACEi or cARB. Mean cumulative dose was 236&#x2009;mg/kg (calculated as equivalent ramipril dose). Cumulative cACEi/cARB dose was not protective against SLE-CD. Caucasian ethnicity, current employment status and azathioprine cumulative dose were each associated with reduced odds of SLE-CD. Increasing Fatigue Severity Scale score was associated with increased odds of CD.</AbstractText><AbstractText Label="CONCLUSIONS">In a single-centre SLE cohort, cACEi/cARB use was not associated with absence of CD. Many important confounders may have influenced the results of this retrospective study. A randomised trial is required to accurately determine if cACEi/cARB is a potential treatment for SLE-CD.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Dobrowolski</LastName><ForeName>Chrisanna</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Barraclough</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9698-0917</Identifier><AffiliationInfo><Affiliation>Division of Musculoskeletal &amp; Dermatological Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manchester Academic Health Science Centre, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Jiandong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanic</LastName><ForeName>Milica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bingham</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Mental Health, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruttan</LastName><ForeName>Lesley</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beaton</LastName><ForeName>Dorcas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Work and Health, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wither</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>Maria Carmela</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Krembil Neurosciences Centre, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakvan</LastName><ForeName>Mahta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonilla</LastName><ForeName>Dennisse</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touma</LastName><ForeName>Zahi</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-5177-2076</Identifier><AffiliationInfo><Affiliation>Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada Zahi.Touma@uhn.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>L35JN3I7SJ</RegistryNumber><NameOfSubstance UI="D017257">Ramipril</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017257" MajorTopicYN="N">Ramipril</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</Keyword><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Outcome Assessment, Health Care</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>11</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37429671</ArticleId><ArticleId IdType="pmc">PMC10335417</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000923</ArticleId><ArticleId IdType="pii">10/2/e000923</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahn GY, Kim D, Won S, et al. . Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus 2018;27:1338&#x2013;47. 10.1177/0961203318772021</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318772021</ArticleId><ArticleId IdType="pubmed">29688144</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#x103;rbulescu AL, Sandu RE, Vreju AF, et al. . Neuroinflammation in systemic lupus erythematosus - a review. Rom J Morphol Embryol 2019;60:781&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">31912087</ArticleId></ArticleIdList></Reference><Reference><Citation>Govoni M, Hanly JG. The management of neuropsychiatric lupus in the 21st century: still so many unmet needs. Rheum 2020;59:v52&#x2013;62. 10.1093/rheumatology/keaa404</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa404</ArticleId><ArticleId IdType="pmc">PMC7719041</ArticleId><ArticleId IdType="pubmed">33280014</ArticleId></ArticleIdList></Reference><Reference><Citation>ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature . The American college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis &amp; Rheum
1999;42:599&#x2013;608. 10.1002/1529-0131(199904)42:4&lt;599::AID-ANR2&gt;3.0.CO;2-F
Available: http://doi.wiley.com/10.1002/1529-0131%28199904%2942%3A4%3C%3E1.0.CO%3B2-R</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199904)42:4&lt;599::AID-ANR2&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">10211873</ArticleId></ArticleIdList></Reference><Reference><Citation>Kello N, Anderson E, Diamond B. Cognitive dysfunction in systemic lupus erythematosus: a case for initiating trials. Arthritis Rheum 2019;71:1413&#x2013;25. 10.1002/art.40933</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40933</ArticleId><ArticleId IdType="pmc">PMC6716992</ArticleId><ArticleId IdType="pubmed">31102496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayes HA, Tani C, Kwan A, et al. . What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? a systematic review and meta-analysis. Semin Arthritis Rheum 2018;48:240&#x2013;55. 10.1016/j.semarthrit.2018.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2018.02.007</ArticleId><ArticleId IdType="pubmed">29571540</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen K, Bingham K, Tayer-Shifman OE, et al. . Measures of cognition in rheumatic diseases. Arthritis Care Res (Hoboken) 2020;72 Suppl 10:660&#x2013;75. 10.1002/acr.24364</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24364</ArticleId><ArticleId IdType="pubmed">33091255</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen K, Green R, Bingham K, et al. . Metrics and definitions used in the assessment of cognitive impairment in systemic lupus erythematosus: A systematic review. Semin Arthritis Rheum 2021;51:819&#x2013;30. 10.1016/j.semarthrit.2021.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2021.05.018</ArticleId><ArticleId IdType="pubmed">34157577</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynall M. Neuropsychiatric symptoms in lupus. Lupus 2018;27:18&#x2013;20. 10.1177/0961203318801672</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318801672</ArticleId><ArticleId IdType="pubmed">30452327</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly JG, McCurdy G, Fougere L, et al. . Neuropsychiatric events in systemic lupus erythematosus: Aattribution and clinical significance. J Rheumatol 2004;31:2156&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15517627</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor J, Arinuma Y, Huerta TS, et al. . Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors. J Exp Med 2018;215:2554&#x2013;66. 10.1084/jem.20180776</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180776</ArticleId><ArticleId IdType="pmc">PMC6170183</ArticleId><ArticleId IdType="pubmed">30185634</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob A, Hack B, Chiang E, et al. . C5A alters blood-brain barrier integrity in experimental lupus. FASEB J 2010;24:1682&#x2013;8. 10.1096/fj.09-138834</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.09-138834</ArticleId><ArticleId IdType="pmc">PMC2874478</ArticleId><ArticleId IdType="pubmed">20065106</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirohata S, Arinuma Y, Yanagida T, et al. . Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor Nr2 antibodies in diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res Ther 2014;16. 10.1186/ar4518</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4518</ArticleId><ArticleId IdType="pmc">PMC4060173</ArticleId><ArticleId IdType="pubmed">24655341</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol 2019;15:137&#x2013;52. 10.1038/s41584-018-0156-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0156-8</ArticleId><ArticleId IdType="pmc">PMC8023338</ArticleId><ArticleId IdType="pubmed">30659245</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Li Y, Wang Y, et al. . Intracerebroventricular administration of lupus serum induces Microglia activation and Leukocyte adhesion in the Cerebromicrovasculature of mice. J Neuroimmunol 2019;334. 10.1016/j.jneuroim.2019.576994</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2019.576994</ArticleId><ArticleId IdType="pubmed">31207553</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Hou X, Feng Q, et al. . Lupus serum IgG induces microglia activation through FC fragment dependent way and modulated by B-cell activating factor. J Transl Med 2019;17. 10.1186/s12967-019-02175-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-02175-0</ArticleId><ArticleId IdType="pmc">PMC6925475</ArticleId><ArticleId IdType="pubmed">31864410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Yang C, Zhao Q, et al. . Microglia activation induced by serum of SLE patients. J Neuroimmunol 2017;310:135&#x2013;42. 10.1016/j.jneuroim.2017.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2017.07.010</ArticleId><ArticleId IdType="pubmed">28778438</ArticleId></ArticleIdList></Reference><Reference><Citation>DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem 2016;139 Suppl 2:136&#x2013;53. 10.1111/jnc.13607</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13607</ArticleId><ArticleId IdType="pmc">PMC5025335</ArticleId><ArticleId IdType="pubmed">26990767</ArticleId></ArticleIdList></Reference><Reference><Citation>Nocito C, Lubinsky C, Hand M, et al. . Centrally acting angiotensin-converting enzyme inhibitor suppresses type I interferon responses and decreases inflammation in the periphery and the CNS in lupus-prone mice. Front Immunol 2020;11. 10.3389/fimmu.2020.573677</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.573677</ArticleId><ArticleId IdType="pmc">PMC7522287</ArticleId><ArticleId IdType="pubmed">33042154</ArticleId></ArticleIdList></Reference><Reference><Citation>Dur&#xe1;n-Barrag&#xe1;n S, McGwin G, Vil&#xe1; LM, et al. . Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a Multiethnic US cohort. Rheumatology (Oxford) 2008;47:1093&#x2013;6. 10.1093/rheumatology/ken208</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ken208</ArticleId><ArticleId IdType="pmc">PMC2916239</ArticleId><ArticleId IdType="pubmed">18511474</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi P, Grobe JL, Desland FA, et al. . Direct pro-inflammatory effects of Prorenin on Microglia. PLoS One 2014;9. 10.1371/journal.pone.0092937</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0092937</ArticleId><ArticleId IdType="pmc">PMC4193744</ArticleId><ArticleId IdType="pubmed">25302502</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang EH, Volpe BT, Mackay M, et al. . Selective impairment of spatial cognition caused by autoantibodies to the N-methyl-D-aspartate receptor. EBioMedicine 2015;2:755&#x2013;64. 10.1016/j.ebiom.2015.05.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2015.05.027</ArticleId><ArticleId IdType="pmc">PMC4534689</ArticleId><ArticleId IdType="pubmed">26286205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozora E, Ellison MC, West S. Reliability and validity of the proposed American college of rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004;51:810&#x2013;8. 10.1002/art.20692</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20692</ArticleId><ArticleId IdType="pubmed">15478145</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan R, Wolfson D. The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation: Reitan Neuropsychology. 1985.</Citation></Reference><Reference><Citation>Shapiro AM, Benedict RH, Schretlen D, et al. . Construct and concurrent validity of the Hopkins verbal learning test-revised. Clin Neuropsychol 1999;13:348&#x2013;58. 10.1076/clin.13.3.348.1749</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/clin.13.3.348.1749</ArticleId><ArticleId IdType="pubmed">10726605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacritz LH, Cullum CM, Weiner MF, et al. . Comparison of the Hopkins verbal learning test-revised to the California verbal learning test in Alzheimer's disease. Appl Neuropsychol 2001;8:180&#x2013;4. 10.1207/S15324826AN0803_8</Citation><ArticleIdList><ArticleId IdType="doi">10.1207/S15324826AN0803_8</ArticleId><ArticleId IdType="pubmed">11686654</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Ginzler E, Goldsmith C, et al. . The development and initial validation of the systemic lupus International collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363&#x2013;9. 10.1002/art.1780390303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolski C, McGinley J, Fazzari M, et al. . Association of mycophenolate and azathioprine use with cognitive function in systemic lupus. Rheum 2023;62:1860&#x2013;9. 10.1093/rheumatology/keac540</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac540</ArticleId><ArticleId IdType="pmc">PMC10152298</ArticleId><ArticleId IdType="pubmed">36135792</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Steer RA, Brown GK. Manual for the Beck depression inventory-II psychological corporation. 1996.</Citation></Reference><Reference><Citation>Beck AT, Epstein N, Brown G, et al. . An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893&#x2013;7. 10.1037//0022-006x.56.6.893</Citation><ArticleIdList><ArticleId IdType="doi">10.1037//0022-006x.56.6.893</ArticleId><ArticleId IdType="pubmed">3204199</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150&#x2013;61. 10.1002/pst.433</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pst.433</ArticleId><ArticleId IdType="pmc">PMC3120982</ArticleId><ArticleId IdType="pubmed">20925139</ArticleId></ArticleIdList></Reference><Reference><Citation>Thavaneswaran A, Lix L. Propensity score matching in observational studies [online publication]. 2008.</Citation></Reference><Reference><Citation>Moghaddam B, Beaton D, Green R, et al. . Prevalence of cognitive impairment in an inception lupus cohort as assessed by a comprehensive neuropsychological battery. Arthritis Rheumatol 2019;79:10.</Citation></Reference><Reference><Citation>Lowry E, Puthusseryppady V, Johnen A-K, et al. . Cognitive and neuroimaging markers for Preclinical vascular cognitive impairment. Cereb Circ Cogn Behav 2021;2. 10.1016/j.cccb.2021.100029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cccb.2021.100029</ArticleId><ArticleId IdType="pmc">PMC9616378</ArticleId><ArticleId IdType="pubmed">36324708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingles JL, Boulton DC, Fisk JD, et al. . Preclinical vascular cognitive impairment and Alzheimer disease: neuropsychological test performance 5 years before diagnosis. Stroke 2007;38:1148&#x2013;53. 10.1161/01.STR.0000259716.04739.60</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000259716.04739.60</ArticleId><ArticleId IdType="pubmed">17322075</ArticleId></ArticleIdList></Reference><Reference><Citation>Cope EC, LaMarca EA, Monari PK, et al. . Microglia play an active role in obesity-associated cognitive decline. J Neurosci 2018;38:8889&#x2013;904. 10.1523/JNEUROSCI.0789-18.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0789-18.2018</ArticleId><ArticleId IdType="pmc">PMC6181311</ArticleId><ArticleId IdType="pubmed">30201764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond CA, Blades NJ, Chaudhry SI, et al. . Long-term cognitive decline after newly diagnosed heart failure: longitudinal analysis in the CHS (cardiovascular health study). Circ Heart Fail 2018;11. 10.1161/CIRCHEARTFAILURE.117.004476</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.117.004476</ArticleId><ArticleId IdType="pmc">PMC6072263</ArticleId><ArticleId IdType="pubmed">29523517</ArticleId></ArticleIdList></Reference><Reference><Citation>Devere R. The cognitive consequences of obesity. In: Dementia insights. Practical neurology, 2018.</Citation></Reference><Reference><Citation>Zilliox LA, Chadrasekaran K, Kwan JY, et al. . Diabetes and cognitive impairment. Curr Diab Rep 2016;16. 10.1007/s11892-016-0775-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-016-0775-x</ArticleId><ArticleId IdType="pmc">PMC5528145</ArticleId><ArticleId IdType="pubmed">27491830</ArticleId></ArticleIdList></Reference><Reference><Citation>Leto L, Feola M. Cognitive impairment in heart failure patients. J Geriatr Cardiol 2014;11:316&#x2013;28. 10.11909/j.issn.1671-5411.2014.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.11909/j.issn.1671-5411.2014.04.007</ArticleId><ArticleId IdType="pmc">PMC4294149</ArticleId><ArticleId IdType="pubmed">25593581</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodersen C, Koen E, Ponte A, et al. . Cognitive function in patients with alcoholic and nonalcoholic chronic liver disease. J Neuropsychiatry Clin Neurosci 2014;26:241&#x2013;8. 10.1176/appi.neuropsych.12040091</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.neuropsych.12040091</ArticleId><ArticleId IdType="pubmed">25093764</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber E, Blackstone K, Woods SP. Cognitive Neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action. Neuropsychol Rev 2013;23:81&#x2013;98. 10.1007/s11065-013-9225-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11065-013-9225-6</ArticleId><ArticleId IdType="pmc">PMC3606924</ArticleId><ArticleId IdType="pubmed">23417497</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Tang M-X, Manly J, et al. . Hypertension and the risk of mild cognitive impairment. Arch Neurol 2007;64:1734&#x2013;40. 10.1001/archneur.64.12.1734</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.12.1734</ArticleId><ArticleId IdType="pmc">PMC2672564</ArticleId><ArticleId IdType="pubmed">18071036</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb AJS, Werring DJ. New insights into cerebrovascular pathophysiology and hypertension. Stroke 2022;53:1054&#x2013;64. 10.1161/STROKEAHA.121.035850</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.121.035850</ArticleId><ArticleId IdType="pubmed">35255709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurella M, Chertow GM, Fried LF, et al. . Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2005;16:2127&#x2013;33. 10.1681/ASN.2005010005</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2005010005</ArticleId><ArticleId IdType="pubmed">15888561</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehat P, Atiquzzaman M, Esdaile JM, et al. . Medication Nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 2017;69:1706&#x2013;13. 10.1002/acr.23191</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23191</ArticleId><ArticleId IdType="pubmed">28086003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis MJ, Jawad AS. The effect of Ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology (Oxford) 2017;56:i67&#x2013;77. 10.1093/rheumatology/kew399</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew399</ArticleId><ArticleId IdType="pubmed">27940583</ArticleId></ArticleIdList></Reference><Reference><Citation>Reveille JD, Moulds JM, Ahn C, et al. . Systemic lupus erythematosus in three ethnic groups: I. the effects of HLA class II, C4, and Cr1 Alleles, socioeconomic factors, and Ethnicity at disease onset. LUMINA study group. lupus in minority populations, nature versus nurture. Arthritis Rheum 1998;41:1161&#x2013;72. 10.1002/1529-0131(199807)41:7&lt;1161::AID-ART4&gt;3.0.CO;2-K</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199807)41:7&lt;1161::AID-ART4&gt;3.0.CO;2-K</ArticleId><ArticleId IdType="pubmed">9663471</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez CG, Hamby ME, McReynolds ML, et al. . The role of Apoe4 in disrupting the Homeostatic functions of Astrocytes and Microglia in aging and Alzheimer's disease. Front Aging Neurosci 2019;11:14. 10.3389/fnagi.2019.00014</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00014</ArticleId><ArticleId IdType="pmc">PMC6378415</ArticleId><ArticleId IdType="pubmed">30804776</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyttaris VC. Systemic lupus erythematosus: from genes to organ damage. Methods Mol Biol 2010;662:265&#x2013;83. 10.1007/978-1-60761-800-3_13</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-60761-800-3_13</ArticleId><ArticleId IdType="pmc">PMC3153363</ArticleId><ArticleId IdType="pubmed">20824476</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Choi SJ, Ji JD, et al. . Association between the angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to systemic lupus erythematosus: a meta-analysis. J Renin Angiotensin Aldosterone Syst 2013;14:248&#x2013;54. 10.1177/1470320312459979</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1470320312459979</ArticleId><ArticleId IdType="pubmed">23047029</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjar I, Kritchevsky S, Newman AB, et al. . Renin angiotensin system gene polymorphisms modify angiotensin-converting enzyme inhibitors' effect on cognitive function: the health, aging and body composition study. J Am Geriatr Soc 2010;58:1035&#x2013;42. 10.1111/j.1532-5415.2010.02860.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2010.02860.x</ArticleId><ArticleId IdType="pmc">PMC2926814</ArticleId><ArticleId IdType="pubmed">20722844</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Titov AA, Morel L. An update on lupus animal models. Curr Opin Rheumatol 2017;29:434&#x2013;41. 10.1097/BOR.0000000000000412</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000412</ArticleId><ArticleId IdType="pmc">PMC5815391</ArticleId><ArticleId IdType="pubmed">28537986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul A, Gordon C, Crow MK, et al. . Systemic lupus erythematosus. Nat Rev Dis Primers 2016;2:16039. 10.1038/nrdp.2016.39</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarfeshani A, Carroll KR, Volpe BT, et al. . Correction to: cognitive impairment in SLE: mechanisms and therapeutic approaches. Curr Rheumatol Rep 2021;23:46. 10.1007/s11926-021-01021-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-01021-x</ArticleId><ArticleId IdType="pubmed">33974156</ArticleId></ArticleIdList></Reference><Reference><Citation>Le D, Brown L, Malik K, et al. . Two opposing functions of angiotensin-converting enzyme (ACE) that links hypertension, dementia, and aging. Int J Mol Sci 2021;22. 10.3390/ijms222413178</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222413178</ArticleId><ArticleId IdType="pmc">PMC8707689</ArticleId><ArticleId IdType="pubmed">34947975</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazal K, Perera G, Khondoker M, et al. . Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer's disease. BJPsych Open 2017;3:158&#x2013;64. 10.1192/bjpo.bp.116.004184</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjpo.bp.116.004184</ArticleId><ArticleId IdType="pmc">PMC5495996</ArticleId><ArticleId IdType="pubmed">28713585</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink KM, Leng X, Williamson J, et al. . Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the cardiovascular health study. Arch Intern Med 2009;169:1195&#x2013;202. 10.1001/archinternmed.2009.175</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2009.175</ArticleId><ArticleId IdType="pmc">PMC2881686</ArticleId><ArticleId IdType="pubmed">19597068</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>